Cancer immune contexture and immunotherapy
Introduction
Cancers grow and spread in tissues where the malignant cells interact with blood and lymphatic vessels, stromal cells and hematopoietic cells involved in immune and inflammatory reactions. This landscape constitutes the immune contexture of a tumor which is of paramount importance for patients’ clinical outcome, is predictive of responses to therapies and helps identifying novel targets for immunotherapies [1•].
Section snippets
Clinical impact of the immune contexture in different primary tumors
The immune contexture is a concept that emerged from studies mostly performed in human colorectal cancer (CRC). A comprehensive analysis of a large collection of primary CRC tumors revealed that a high density of intratumoral memory T cells correlates with patients’ longer disease-free (DFS) and overall (OS) survivals [2], confirming a previous report in ovarian cancer [3•]. A closer histopathological analysis of CRC tumors highlighted the fact that the T cells were not stochastically
Clinical impact of the immune contexture in metastatic sites
It is intuitively thought that tumor progression is accompanied by tumor escape from the immune system [28]. If this escape linearly followed cancer progression, the immune contexture of metastatic sites should not impact clinical outcome. However, high densities of CD8+ T cells in hepatic and lung metastases of CRC correlate with longer OS [25], as in primary CRC [4••]. Densities of infiltrating immune cells were shown to be correlated between the primary tumors and matched metastases [25].
Clinical impact of the immune contexture within a given cancer
Whole genome transcriptomic analyses provide a novel way to classify subgroups in a given cancer type. These unsupervised approaches complement genomic classifications by identifying malignant cell subgroups with distinct functional traits. We undertook an analysis of the expression of immune genes and the concomitant immune cell infiltration in cohorts of various human cancers. To precisely analyze the immune contexture of large collections of human cancers, we established transcriptomic
The immune contexture and response to therapy
The immune microenvironment of tumors not only reflects the oncogenic processes of a cancer in a patient, but is also a constitutive arm of cancer control and thus of patient's clinical outcome. It is therefore likely that therapeutic interventions modifying the immune contexture will result in profound changes in cancer evolution. Characterizing the immune contexture or the corresponding molecular profile of a tumor in a patient will allow clinicians to propose the most appropriate therapies.
Financial support
This work was supported by the ‘Institut National de la Santé et de la Recherche Médicale’, the University Paris-Descartes, the University Pierre et Marie Curie, the Institut National du Cancer (2009-1-PLBIO-07-INSERM 6-1, 2010-1-PLBIO-03-INSERM 6-1, 2011-1-PLBIO-06-INSERM 6-1), CARPEM (CAncer Research for PErsonalized Medicine), Labex Immuno-Oncology (LAXE62_9UMS872 FRIDMAN, 11LAXE62_9UMS872 FRIDMAN), and the Fondation ARC pour la Rercherche sur le Cancer (SL220110603483), the Universidad de
References and recommended reading
Papers of particular interest, published within the period of review, have been highlighted as:
• of special interest
•• of outstanding interest
Acknowledgements
We thank the members of the teams of I. Cremer/J.L. Teillaud and J. Galon at the Cordeliers Research Center for their fruitful discussions and who performed most of the work cited in this review.
References (41)
- et al.
Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells
Cancer Res
(2014) - et al.
Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer
Am J Respir Crit Care Med
(2014) - et al.
Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma
Cancer Res
(2011) - et al.
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape
Sci Transl Med
(2012) - et al.
Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation
Cancer Immunol Res
(2014) - et al.
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
Clin Cancer Res
(2014) - et al.
The immune contexture in human tumours: impact on clinical outcome
Nat Rev Cancer
(2012) - et al.
Effector memory T cells, early metastasis, and survival in colorectal cancer
N Engl J Med
(2005) - et al.
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
N Engl J Med
(2003) - et al.
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Science
(2006)
Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer
Gastroenterology
Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer
Immunity
Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures
J Clin Oncol
Tertiary lymphoid structures in cancer and beyond
Trends Immunol
Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer
Cancer Res
CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma
Am J Clin Pathol
Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma
J Clin Oncol
Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma
Cancer
The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients
BMC Cancer
Cited by (126)
Recent advance in nanomaterials for cancer immunotherapy
2022, Chemical Engineering JournalE2F3/5/8 serve as potential prognostic biomarkers and new therapeutic direction for human bladder cancer
2024, Medicine (United States)
- 4
These authors contributed equally to this work.